FDA approves Checkpoint Therapeutics’ Unloxcyt for advanced cSCC

Shares of Checkpoint Therapeutics, Inc. rose 4.6% to $3.84 in post-market trading after the US Food and Drug Administration (FDA) approved Unloxcyt (cosibelimab-ipdl) treatment for ... Read More